In this section
Assorted resources on conditions connected to Cardiology.
Latest information on diseases in Dermatology.
A detailed look at conditions connected to Endocrinology.
Gastroenterology and Hepatology
In-depth material on Gastroenterology and Hepatology.
Assorted resources on conditions connected to Haematology.
A detailed look at conditions connected to Infectious Diseases.
Neurology (CNS) and Pain
Learning materials and guidelines on Neurology (CNS) and Pain.
A detailed look at conditions connected to Oncology.
In-depth material on Respiratory conditions.
Latest information on diseases in Rheumatology.
Learning materials and guidelines on Urology.
Bristol Myers Squibb announced that Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with Cabometyx (cabozantinib) 40 mg once daily tablets was approved by the FDA for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
You may be interested in...
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations.